抗體藥物複合體契約製造市場規模、佔有率、成長分析（按開發階段、製程組件、目標指示、抗體生成、抗體來源和地區）- 產業預測 2025-2032

預計 2023 年全球抗體藥物複合體契約製造市場價值將達到 86 億美元，並將從 2024 年的 96.4 億美元成長到 2032 年的 240.4 億美元，預測期內（2025-2032 年）的複合年成長率為 12.1%。

根據市場洞察，全球抗體藥物複合體(ADC)契約製造製造業正在經歷顯著成長，這得益於對標靶癌症治療的日益成長的偏好以及對生技藥品研發的大量投資。全球癌症發生率的上升推動了對精準醫療的需求，使 ADC 成為值得關注的治療選擇。此外，ADC 的製造複雜性需要生物偶聯專業知識、先進的控制和分析測試，從而創造了新的商機。在 FDA 和 EMA 等監管機構的快速核准支持下，這將進一步刺激需求。相反，高製造成本、嚴格的法律規範、缺乏專業的契約製造組織 (CMO) 以及供應鏈問題等挑戰可能會在不久的將來阻礙市場成長和滲透。

目錄

介紹

• 調查目標
• 調查範圍
• 定義

調查方法

• 資訊收集
• 二次資料和一次資料方法
• 市場規模預測
• 市場假設與約束

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分市場機會分析

市場動態與展望

• 市場概況
• 市場規模
• 市場動態
  • 促進因素和機遇
  • 限制與挑戰
• 波特的分析

關鍵市場考察

• 關鍵成功因素
• 競爭程度
• 關鍵投資機會
• 市場生態系統
• 市場吸引力指數（2024年）
• PESTEL分析
• 總體經濟指標
• 價值鏈分析
• 定價分析
• 監管格局
• 原料分析

抗體藥物複合體契約製造市場規模（按發展階段和複合年成長率）（2025-2032）

• 市場概況
• 第一階段
• 第二階段
• 第三階段

抗體藥物複合體契約製造市場規模（按製程組件和複合年成長率）（2025-2032）

• 市場概況
• 抗體
• HPAPI/細胞毒性有效載荷
• 鍵/連接子
• 填充/整理

抗體藥物複合體契約製造市場規模（按目標適應症和複合年成長率）（2025-2032）

• 市場概況
• 固態腫瘤
• 血液系統腫瘤
• 其他

抗體藥物複合體契約製造市場規模（以抗體生成和複合年成長率）（2025-2032）

• 市場概況
• 第二代
• 第三代
• 第四代
• 新一代

抗體藥物複合體契約製造市場規模（按抗體來源和複合年成長率）（2025-2032）

• 市場概況
• 人性化
• 嵌合體
• 老鼠
• 其他

抗體藥物複合體契約製造市場規模（按連接體類型和複合年成長率）（2025-2032）

• 市場概況
• 馬來醯亞胺
• SMCC
• 四肽基連接體
• 纈氨酸-瓜氨酸
• 其他

抗體藥物複合體契約製造市場規模（按最終用戶和複合年成長率分類）（2025-2032）

• 市場概況
• 製藥公司
• 生技公司-30%
• 學術研究機構
• 其他

抗體藥物複合體契約製造市場規模及複合年成長率（2025-2032）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前五大公司對比
• 主要企業市場定位（2024年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市佔率分析（2024年）
• 主要企業簡介
  • 公司詳情
  • 產品系列分析
  • 公司佔有率按部門分析
  • 收益同比比較（2022-2024 年）

主要企業簡介

• Lonza Group AG（Switzerland）
• WuXi XDC（China）
• Catalent, Inc.（USA）
• Piramal Pharma Solutions（India）
• MilliporeSigma（Germany）
• Sterling Pharma Solutions（UK）
• AGC Biologics（USA）
• Cerbios-Pharma SA（Switzerland）
• CARBOGEN AMCIS（Switzerland）
• Curia（USA）
• Abzena PLC（UK）
• WuXi Biologics（Cayman Islands）
• Ajinomoto Bio-Pharma Services（Japan）
• Axplora（France）
• Sartorius AG（Germany）
• Samsung Biologics（South Korea）
• Recipharm AB（Sweden）
• AbbVie Contract Manufacturing（USA）
• Formosa Laboratories（Taiwan）
• Veranova（USA）

結論和建議

Global Antibody Drug Conjugates Contract Manufacturing Market size was valued at USD 8.6 billion in 2023 and is poised to grow from USD 9.64 billion in 2024 to USD 24.04 billion by 2032, growing at a CAGR of 12.1% during the forecast period (2025-2032).

Market insights indicate a significant uptick in the global antibody drug conjugates (ADCs) contract manufacturing sector, driven by the rising preference for targeted cancer therapies and substantial investments in biologics R&D. The increasing prevalence of cancer globally has fueled the demand for precision medicine, positioning ADCs as a notable treatment option. Moreover, the complexity involved in ADC manufacturing-requiring specialized bioconjugation expertise, advanced containment, and analytical testing-presents new business opportunities. Support from regulatory bodies, including the FDA and EMA, through expedited approvals enhances demand further. Conversely, challenges such as high manufacturing costs, stringent regulatory frameworks, a scarcity of specialized contract manufacturing organizations (CMOs), and supply chain issues may impede market growth and penetration in the near future.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Antibody Drug Conjugates Contract Manufacturing market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Antibody Drug Conjugates Contract Manufacturing Market Segments Analysis

Global Antibody Drug Conjugates Contract Manufacturing Market is segmented by Stage of Development, Process Component, Target Indication, Antibody Generation, Antibody Origin, Type of Linker, End User and region. Based on Stage of Development, the market is segmented into Phase I, Phase II and Phase III. Based on Process Component, the market is segmented into Antibody, HPAPI / Cytotoxic Payload, Conjugation / Linker and Fill / Finish. Based on Target Indication, the market is segmented into Solid Tumors, Hematological Tumors and Others. Based on Antibody Generation, the market is segmented into Second Generation, Third Generation, Fourth Generation and Next Generation. Based on Antibody Origin, the market is segmented into Humanized, Chimeric, Murine and Others. Based on Type of Linker, the market is segmented into Maleimide, SMCC, Tetrapeptide-based linker, Valine-citrulline and Others. Based on End User, the market is segmented into Pharmaceutical Companies, Biotechnology Companies - 30%, Academic & Research Institutes and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Antibody Drug Conjugates Contract Manufacturing Market

The expanding therapeutic applications of various antibody drug conjugates have prompted pharmaceutical and biotech companies to enhance their investments in research and development. As clinical trials advance, there is a heightened demand for manufacturing partners that can provide scalable and compliant production solutions. Furthermore, the rising number of approvals for antibody drug conjugates globally is anticipated to generate additional opportunities for contract manufacturing firms specializing in this sector, thereby driving growth and innovation within the Global Antibody Drug Conjugates Contract Manufacturing market. The overall landscape remains dynamic, reflecting the increasing importance of these advanced therapeutics.

Restraints in the Global Antibody Drug Conjugates Contract Manufacturing Market

The global market for antibody drug conjugates contract manufacturing faces several challenges that could impede its growth. The complexity of the design, development, and production processes necessitates specialized facilities capable of handling antibodies, cytotoxic drugs, and conjugation, leading to substantial capital investments. Additionally, the high costs associated with research and development, stemming from the rigorous preclinical and clinical testing required to demonstrate safety and efficacy, may act as a barrier to demand. Such financial strains could hinder the viability and expansion of the contract manufacturing sector within this niche pharmaceutical market.

Market Trends of the Global Antibody Drug Conjugates Contract Manufacturing Market

The Global Antibody Drug Conjugates Contract Manufacturing market is witnessing a robust trend towards strategic collaborations and capacity expansions among contract manufacturing organizations (CMOs). Companies in this sector are prioritizing the establishment of partnerships with pharmaceutical innovators to create secure supply chains and ensure dedicated manufacturing slots, thereby mitigating potential bottlenecks. Additionally, the ongoing demand for scalable and flexible manufacturing solutions is driving CMOs to enhance their operational capabilities. This focus on maximizing business scope and flexibility is expected to solidify the role of antibody drug conjugates in innovative therapeutics, shaping a dynamic landscape in the contract manufacturing market.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Landscape
• Raw Material Analysis

Global Antibody Drug Conjugates Contract Manufacturing Market Size by Stage of Development & CAGR (2025-2032)

• Market Overview
• Phase I
• Phase II
• Phase III

Global Antibody Drug Conjugates Contract Manufacturing Market Size by Process Component & CAGR (2025-2032)

• Market Overview
• Antibody
• HPAPI / Cytotoxic Payload
• Conjugation / Linker
• Fill / Finish

Global Antibody Drug Conjugates Contract Manufacturing Market Size by Target Indication & CAGR (2025-2032)

• Market Overview
• Solid Tumors
• Hematological Tumors
• Others

Global Antibody Drug Conjugates Contract Manufacturing Market Size by Antibody Generation & CAGR (2025-2032)

• Market Overview
• Second Generation
• Third Generation
• Fourth Generation
• Next Generation

Global Antibody Drug Conjugates Contract Manufacturing Market Size by Antibody Origin & CAGR (2025-2032)

• Market Overview
• Humanized
• Chimeric
• Murine
• Others

Global Antibody Drug Conjugates Contract Manufacturing Market Size by Type of Linker & CAGR (2025-2032)

• Market Overview
• Maleimide
• SMCC
• Tetrapeptide-based linker
• Valine-citrulline
• Others

Global Antibody Drug Conjugates Contract Manufacturing Market Size by End User & CAGR (2025-2032)

• Market Overview
• Pharmaceutical Companies
• Biotechnology Companies - 30%
• Academic & Research Institutes
• Others

Global Antibody Drug Conjugates Contract Manufacturing Market Size & CAGR (2025-2032)

• North America (Stage of Development, Process Component, Target Indication, Antibody Generation, Antibody Origin, Type of Linker, End User)
  • US
  • Canada
• Europe (Stage of Development, Process Component, Target Indication, Antibody Generation, Antibody Origin, Type of Linker, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Stage of Development, Process Component, Target Indication, Antibody Generation, Antibody Origin, Type of Linker, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Stage of Development, Process Component, Target Indication, Antibody Generation, Antibody Origin, Type of Linker, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Stage of Development, Process Component, Target Indication, Antibody Generation, Antibody Origin, Type of Linker, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Lonza Group AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• WuXi XDC (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Catalent, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Piramal Pharma Solutions (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• MilliporeSigma (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sterling Pharma Solutions (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AGC Biologics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cerbios-Pharma SA (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CARBOGEN AMCIS (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Curia (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abzena PLC (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• WuXi Biologics (Cayman Islands)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ajinomoto Bio-Pharma Services (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Axplora (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sartorius AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Samsung Biologics (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Recipharm AB (Sweden)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Contract Manufacturing (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Formosa Laboratories (Taiwan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Veranova (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations